Optimization of insulin therapy in patients with Type 2 diabetes mellitus: beyond basal insulin
Article first published online: 19 JUN 2012
© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK
Volume 29, Issue 7, pages e13–e20, July 2012
How to Cite
Blak, B. T., Smith, H. T., Hards, M., Curtis, B. H. and Ivanyi, T. (2012), Optimization of insulin therapy in patients with Type 2 diabetes mellitus: beyond basal insulin. Diabetic Medicine, 29: e13–e20. doi: 10.1111/j.1464-5491.2012.03586.x
- Issue published online: 19 JUN 2012
- Article first published online: 19 JUN 2012
- Accepted manuscript online: 24 JAN 2012 06:55AM EST
- Accepted 18 January 2012
- basal insulin;
- prandial insulin;
- premixed insulin;
- Type 2 diabetes;
- UK General Practice
Diabet. Med. 29, e13–e20 (2012)
Aims To describe patients with Type 2 diabetes mellitus treated with basal insulin, with or without oral antidiabetics in UK primary care, and evaluate insulin treatment patterns and factors explaining changes in therapy.
Methods Retrospective analysis of patients with Type 2 diabetes within The Health Improvement Network UK primary care database. Patients receiving basal insulin between January and June 2006 were followed until July 2009.
Results Analysis included 3185 patients, mean age 65.6 years [standard deviation (SD) 12.4], 50.9% men, median diabetes duration 9.6 years, median basal insulin use 1.3 years, 86.5% had received oral antidiabetics in the previous 12 months. Mean follow-up was 2.9 years (SD 1.0), 59.8% patients maintained basal insulin throughout follow-up with a mean HbA1C of 69 mmol/mol (SD 19; 8.4%, SD 1.7) at baseline and 65 mmol/mol (SD 17; 8.1%, SD 1.6) during follow-up. During follow-up, 6.9% of patients discontinued, 19.3% intensified with and 14.1% switched to prandial or premixed insulin. Patients who intensified (prandial) had a mean HbA1c of 77 mmol/mol (SD 18; 9.2%, SD 1.6) before change and a mean HbA1c of 71 mmol/mol (SD 21; 8.6%, SD 2.0) at the end of the study. Those switching to premixed insulin had a mean HbA1c of 80 mmol/mol (SD 18; 9.5%, SD 1.7) before change and a mean HbA1c of 69 mmol/mol (SD 17; 8.5%, SD 1.5) at the end of the study. Increasing HbA1c and longer diabetes duration explained intensification and switch.
Conclusions The majority of patients had HbA1c above the 53 mmol/mol (< 7%) target at baseline and post-intensification/switch. The HbA1c levels were reduced by intensification/switch suggesting that insulin changes did have some impact. Most patients did not change insulin treatment despite having higher than recommended HbA1c levels. Reasons for not changing treatment in face of unsatisfactory clinical outcomes are unclear. Further research is warranted to explore barriers towards therapy change.